SOPHiA GENETICS (NasdaqGS:SOPH) has wrapped up FY 2025 with Q4 revenue of US$21.7 million and a basic EPS loss of US$0.28, while trailing twelve month figures show revenue of US$77.3 million and a basic EPS loss of US$1.17. The company has seen revenue move from US$17.7 million in Q4 2024 to US$21.7 million in Q4 2025 and quarterly basic EPS shift from a loss of US$0.23 to a loss of US$0.28. This sets up a results season where investors are weighing top line momentum against ongoing pressure on margins.

See our full analysis for SOPHiA GENETICS.

With the headline numbers on the table, the next step is to see how this mix of revenue growth and continuing losses lines up with the dominant bull and bear stories around SOPHiA GENETICS.

See what the community is saying about SOPHiA GENETICS

TTM losses approach US$79 million

• On a trailing twelve month basis, SOPHiA GENETICS reported US$77.3 million in revenue against a net loss of US$79.0 million and basic EPS of a US$1.17 loss, so the company is still spending roughly as much as it brings in.
• Bears argue that persistent losses and high cash burn could limit flexibility, and the TTM net loss moving from US$62.5 million in 2024 Q4 to US$79.0 million in 2025 Q4, together with quarterly net income staying negative between US$17.4 million and US$22.4 million through 2025, supports the cautious view that profitability is not yet within reach.
  • The risk summary also notes no forecasted path to profitability over the next three years, which fits with TTM EPS staying around a US$1 loss across the last six quarters.
  • Critics highlight that losses have been widening at about 4% per year over the past five years, and the 2025 Q4 net loss of US$19.2 million versus US$15.2 million in 2024 Q4 lines up with that concern.

Stay grounded in the numbers before you lean into the cautious case, because the earnings path and cash burn are doing a lot of the talking here. 🐻 SOPHiA GENETICS Bear Case

Revenue growth meets rich P/S multiple

• Revenue is forecast to grow around 19.6% per year while the current P/S of 3.7x sits above both the 1.1x peer average and the 2.2x US Healthcare Services average, so the market is already paying more per dollar of sales than for many comps.
• Supporters of the bullish view point to that growth profile and higher pricing as signs of a growth story, but the premium P/S means the case really depends on revenue delivering as expected rather than stalling.
  • The TTM revenue line in the data has stepped from US$64.5 million in 2024 Q3 to US$77.3 million in 2025 Q4, which fits the growth angle bulls talk about.
  • At the same time, the valuation risk flagged in the analysis, with SOPHiA screening as more expensive than peers on P/S, shows how sensitive the stock could be if that 19.6% revenue growth expectation changes.

Analyst upside vs current share price

• Analyst targets as a group point to 81.5% upside from the current US$4.23 share price if the stock were to reach the allowed reference price of US$7.67, which is well above where it trades today.
• What stands out in the bullish narrative is how much of that expected upside leans on stronger revenue and margin progress, while the balanced and bearish takes keep circling back to the fact that analysts do not project SOPHiA GENETICS to be profitable within the next three years.
  • The forecasts in the narratives talk about revenue growth between roughly 17% and 25.6% a year and eventual profit margins converging toward an 8.8% industry level by around 2028, yet the latest TTM net loss of US$79.0 million underlines how far current earnings are from those scenarios.
  • Given that backdrop, the 81.5% implied upside mainly reflects confidence in those forward assumptions rather than anything visible yet in EPS, which is still a US$1.17 loss on a TTM basis.

If you want to see how these bullish expectations stack up against the actual earnings path, the full bull case narrative on SOPHiA GENETICS is worth a closer look. 🐂 SOPHiA GENETICS Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for SOPHiA GENETICS on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Balancing those bullish and cautious takes is not easy, so move quickly to check the details yourself and form your own opinion by starting with 2 key rewards and 1 important warning sign.

See What Else Is Out There

SOPHiA GENETICS is still reporting sizeable losses, with TTM net loss of US$79.0 million, no forecasted path to profitability, and a premium P/S multiple.

If that mix of ongoing losses and valuation risk feels uncomfortable, you may wish to shift your focus toward companies with steadier profiles and check out our 77 resilient stocks with low risk scores that may better match your risk tolerance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.